Identifying premenopausal patients with early-stage hormone receptor–positive breast cancer at minimal risk of distant recurrence by breast cancer index

Key Points

• Patients estimated to have minimal-risk of distant recurrence within 10 years were identified using the BCI cutpoint—this is significant for treatment decisions.
• The prognostic ability of the minimal-risk BCI cutpoint was confirmed in premenopausal patients with hormone-receptor-positive breast cancer.
• BCI cutpoint classification can help in personalizing adjuvant endocrine therapy in patients treated for early-stage breast cancer conditions.
• Findings suggest that careful patient selection may reduce unnecessary treatments and focus on effective therapy.